Back to resultsA Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma
Primary Purpose
Multiple Myeloma
Status
Completed
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
AMG 224
Sponsored by
About this trial
This is an interventional treatment trial for Multiple Myeloma focused on measuring Multiple Myeloma, Relapsed Multiple Myeloma, Refractory Multiple Myeloma
Eligibility Criteria
Inclusion Criteria:
- Pathologically documented,multiple myeloma relapsed or refractory progressive disease after at least 3 lines of therapy for multiple myeloma.
Prior therapeutic treatment or regimens must include proteasome inhibitors (e.g. bortezomib) and immunomodulatory drugs (e.g. lenalidomide).
- Willing and able to undergo bone marrow aspirate per protocol (with or without bone marrow biopsy per institutional guidelines).
- Measurable disease per the International Myeloma Working Group (IMWG) response criteria
- Hematological function, as follows, without transfusion support:
- Absolute neutrophil count ≥ 1.0 X 10^9/L,
- Platelet count ≥ 75 X 10^9/L (in patients with < 50% of bone marrow nucleated cells were plasma cells) or ≥ 50 X 10^9/L (in patients with ≥ 50% of bone marrow nucleated cells were plasma cells) without transfusion or growth factor support
- Hemoglobin > 8 g/dL (> 80 g/L)
- Adequate renal and hepatic function
- Left ventricular ejection fraction (LVEF) > 50%
Exclusion Criteria:
- Currently receiving treatment in another investigational device or drug study, or less than 28 days since ending treatment on another investigational device or drug study
- Autologous stem cell transplant less than 90 days prior to study day 1
- Multiple myeloma with IgM subtype
- POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) syndrome, Plasma cell leukemia, Waldenstrom's macroglobulinemia or Amyloidosis
- Glucocorticoid therapy (prednisone > 30 mg/day or equivalent) within 7 days prior to study day
- Myocardial infarction within 6 months of study day 1, symptomatic congestive heart failure (New York Heart Association > class II)
- A baseline ECG QTcF > 470 msec
- Anti-tumor therapy (chemotherapy, antibody therapy, molecular targeted therapy, or investigational agent) within 28 days prior to study day 1
Sites / Locations
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm 7
Arm 8
Arm 9
Arm Type
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Arm Label
Dose Exploration: AMG 224 Dose A
Dose Exploration: AMG 224 Dose B
Dose Exploration: AMG 224 Dose C
Dose Exploration: AMG 224 Dose D
Dose Exploration: AMG 224 Dose E
Dose Exploration: AMG 224 Dose F
Dose Exploration: AMG 224 Dose G
Dose Expansion: AMG 224 Dose H + prior CD38 targeting antibody treatment
Dose Expansion: AMG 224 Dose H + no prior CD38 targeting antibody treatment
Arm Description
Participants were administered AMG 224 Dose A as an intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle, where each cycle is 3 weeks.
Participants were administered AMG 224 Dose B as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Participants were administered AMG 224 Dose C as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Participants were administered AMG 224 Dose D as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Participants were administered AMG 224 Dose E as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Participants were administered AMG 224 Dose F as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Participants were administered AMG 224 Dose G as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Participants who had prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the maximum tolerated dose [MTD] based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Participants who had no prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the MTD based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Outcomes
Primary Outcome Measures
Number of Participants Who Experienced a Dose-Limiting Toxicity (DLT)
Adverse events, including DLTs, were graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. A DLT was considered as any of the below, if judged by the investigator to be possibly related to AMG 224:
Hematological:
Grade 4 neutropenia lasting > 7 days
Grade 3 or 4 neutropenia with fever > 38.5°C
Grade 3 thrombocytopenia with ≥ Grade 2 hemorrhage
Grade 4 thrombocytopenia lasting > 7 days
Grade 3 anemia with symptoms or required intervention
Grade 4 anemia
Lymphopenia is not considered a DLT
Non-hematological:
≥ Grade 3 nausea, vomiting or diarrhea persisting > 3 days despite optimal medical support
Grade 3 fatigue persisting > 7 days
≥ Grade 3 acute kidney injury lasting > 3 days
Elevation of aspartate aminotransferase or alanine aminotransferase >3x to >8x upper limit of normal (ULT) dependent on criteria
Total bilirubin > 3x ULN
Participants meeting the criteria for Hy's Law case were considered to have a DLT.
Number of Participants With a Treatment-emergent Adverse Event (TEAE)
An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant.
TEAEs were any AE that occurred after receiving at least 1 dose of treatment.
Treatment-related TEAEs were those considered related to study treatment by the investigator.
Any clinically significant changes in ECGs, vital signs, physical examination with a neurologic assessment and clinical laboratory tests were recorded as TEAEs.
Secondary Outcome Measures
Maximum Observed Concentration (Cmax) of AMG 224
Cmax of AMG 224 conjugated antibody, total anti-B-cell maturation antigen (anti-BCMA) antibody and DM1 was measured. DM1 is a semi-synthetic derivative of the ansamycin antibiotic, maytansine conjugated to the non-cleavable linker 4-[N-maleimidomethyl] cyclohexane-1-carboxylate conjugated to lysine residues in the antibody (MCC).
Minimum Observed Concentration (Cmin) of AMG 224
Cmin of AMG 224 conjugated antibody, total anti-BCMA antibody and DM1 was measured.
Area Under the Concentration-time Curve (AUC) of AMG 224
AUC of AMG 224 conjugated antibody, total anti-B-cell maturation antigen (anti-BCMA) antibody and DM1 was measured.
Clearance (CL) of AMG 224
CL of AMG 224 conjugated antibody, total anti-B-cell maturation antigen (anti-BCMA) antibody and DM1 was measured.
Half-life (t1/2) of AMG 224
t1/2 of AMG 224 conjugated antibody, total anti-B-cell maturation antigen (anti-BCMA) antibody and DM1 was measured.
Best Overall Response (BOR) According to International Myeloma Working Group Uniform Response Criteria (IMWG-URC)
BOR was the best observed post baseline disease response per IMWG-URC:
Stringent Complete Response (sCR): Negative immunofixation on the serum and urine, soft tissue plasmacytomas disappearance, < 5% plasma cells in bone marrow (BM). Normal serum free light chain ratio and absence of clonal cells in BM Very Good Partial Response (PR[VGPR]): Serum and urine M-protein detectable by immunofixation or ≥ 90% reduction in serum M-protein (urine M-protein level < 100 mg/24-h) PR: ≥ 50% reduction of serum M-protein and 24-hour (h) urinary M-protein by ≥ 90% or to < 200 mg/ 24-h Minor Response (MR): 25%-49% reduction of serum M-protein and 50%-89% in 24-h urinary M-protein, exceeding 200 mg/ 24-h Stable Disease (SD): Not meeting criteria above Progressive Disease (PD): ≥ 25% increase from lowest response value in serum. Development of new or increased size of existing bone lesions or soft tissue plasmacytomas. Hypercalcemia attributed to the plasma cell proliferative disorder
Time To Progression (TTP) According to International Myeloma Working Group Uniform Response Criteria (IMWG-URC)
TTP was the time from the first administration of AMG 224 to the first objective assessment of disease progression as per IMWG-URC or deaths or if applicable date of censoring.
Duration of Response (DOR) According to International Myeloma Working Group Uniform Response Criteria (IMWG-URC)
DOR was defined as the time between the date of the first observation indicating an objective response as PR (or better) through to the subsequent date of disease progression as classified by per the IMWG-URC for Multiple Myeloma or death or where applicable date of censoring.
Percentage of Participants With Conversion to Minimal Residual Disease (MRD)-Negativity
MRD negative was defined as a tumor load of less than 1 clonal cell in 105 normal cells (as determined by flow cytometry). The percentage of participants who converted to be MRD negative was calculated.
Number of Participants With an Anti-AMG 224 Antibody Formation
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02561962
Brief Title
A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma
Official Title
A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 224 in Subjects With Relapsed or Refractory Multiple Myeloma
Study Type
Interventional
2. Study Status
Record Verification Date
October 2022
Overall Recruitment Status
Completed
Study Start Date
November 20, 2015 (Actual)
Primary Completion Date
November 30, 2018 (Actual)
Study Completion Date
April 22, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Amgen
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is a first in human phase 1 multicenter open label study in subjects with relapsed or refractory multiple myeloma.
Detailed Description
This is a first in human phase 1 multicenter open label study to evaluate the safety and tolerability of AMG 224 in subjects with relapsed or refractory multiple myeloma. The study will be conducted in 2 parts. Part 1 is the dose-exploration and part 2 is the dose-expansion. Study medication will be administered once every 3 weeks by intravenous (IV) infusion.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Multiple Myeloma
Keywords
Multiple Myeloma, Relapsed Multiple Myeloma, Refractory Multiple Myeloma
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
42 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Dose Exploration: AMG 224 Dose A
Arm Type
Experimental
Arm Description
Participants were administered AMG 224 Dose A as an intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle, where each cycle is 3 weeks.
Arm Title
Dose Exploration: AMG 224 Dose B
Arm Type
Experimental
Arm Description
Participants were administered AMG 224 Dose B as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Arm Title
Dose Exploration: AMG 224 Dose C
Arm Type
Experimental
Arm Description
Participants were administered AMG 224 Dose C as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Arm Title
Dose Exploration: AMG 224 Dose D
Arm Type
Experimental
Arm Description
Participants were administered AMG 224 Dose D as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Arm Title
Dose Exploration: AMG 224 Dose E
Arm Type
Experimental
Arm Description
Participants were administered AMG 224 Dose E as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Arm Title
Dose Exploration: AMG 224 Dose F
Arm Type
Experimental
Arm Description
Participants were administered AMG 224 Dose F as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Arm Title
Dose Exploration: AMG 224 Dose G
Arm Type
Experimental
Arm Description
Participants were administered AMG 224 Dose G as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Arm Title
Dose Expansion: AMG 224 Dose H + prior CD38 targeting antibody treatment
Arm Type
Experimental
Arm Description
Participants who had prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the maximum tolerated dose [MTD] based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Arm Title
Dose Expansion: AMG 224 Dose H + no prior CD38 targeting antibody treatment
Arm Type
Experimental
Arm Description
Participants who had no prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the MTD based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
Intervention Type
Drug
Intervention Name(s)
AMG 224
Intervention Description
Administered as an IV infusion.
Primary Outcome Measure Information:
Title
Number of Participants Who Experienced a Dose-Limiting Toxicity (DLT)
Description
Adverse events, including DLTs, were graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. A DLT was considered as any of the below, if judged by the investigator to be possibly related to AMG 224:
Hematological:
Grade 4 neutropenia lasting > 7 days
Grade 3 or 4 neutropenia with fever > 38.5°C
Grade 3 thrombocytopenia with ≥ Grade 2 hemorrhage
Grade 4 thrombocytopenia lasting > 7 days
Grade 3 anemia with symptoms or required intervention
Grade 4 anemia
Lymphopenia is not considered a DLT
Non-hematological:
≥ Grade 3 nausea, vomiting or diarrhea persisting > 3 days despite optimal medical support
Grade 3 fatigue persisting > 7 days
≥ Grade 3 acute kidney injury lasting > 3 days
Elevation of aspartate aminotransferase or alanine aminotransferase >3x to >8x upper limit of normal (ULT) dependent on criteria
Total bilirubin > 3x ULN
Participants meeting the criteria for Hy's Law case were considered to have a DLT.
Time Frame
Day 1 to Day 28
Title
Number of Participants With a Treatment-emergent Adverse Event (TEAE)
Description
An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant.
TEAEs were any AE that occurred after receiving at least 1 dose of treatment.
Treatment-related TEAEs were those considered related to study treatment by the investigator.
Any clinically significant changes in ECGs, vital signs, physical examination with a neurologic assessment and clinical laboratory tests were recorded as TEAEs.
Time Frame
Day 1 of Cycle 1 to up to the end of Cycle 4, where each cycle is 3 weeks; up to 12 weeks.
Secondary Outcome Measure Information:
Title
Maximum Observed Concentration (Cmax) of AMG 224
Description
Cmax of AMG 224 conjugated antibody, total anti-B-cell maturation antigen (anti-BCMA) antibody and DM1 was measured. DM1 is a semi-synthetic derivative of the ansamycin antibiotic, maytansine conjugated to the non-cleavable linker 4-[N-maleimidomethyl] cyclohexane-1-carboxylate conjugated to lysine residues in the antibody (MCC).
Time Frame
AMG 224: Cycles 1-4 (each cycle = 3 weeks): pre-dose and 0 to 336 hours post-dose; Cycles 5 onwards: pre-dose to 37 days post last dose. DM1: Cycles 1-2 only: pre-dose and 0 to 96 hours post-dose.
Title
Minimum Observed Concentration (Cmin) of AMG 224
Description
Cmin of AMG 224 conjugated antibody, total anti-BCMA antibody and DM1 was measured.
Time Frame
AMG 224: Cycles 1-4 (each cycle = 3 weeks): pre-dose and 0 to 336 hours post-dose; Cycles 5 onwards: pre-dose to 37 days post last dose. DM1: Cycles 1-2 only: pre-dose and 0 to 96 hours post-dose.
Title
Area Under the Concentration-time Curve (AUC) of AMG 224
Description
AUC of AMG 224 conjugated antibody, total anti-B-cell maturation antigen (anti-BCMA) antibody and DM1 was measured.
Time Frame
AMG 224: Cycles 1-4 (each cycle = 3 weeks): pre-dose and 0 to 336 hours post-dose; Cycles 5 onwards: pre-dose to 37 days post last dose. DM1: Cycles 1-2 only: pre-dose and 0 to 96 hours post-dose.
Title
Clearance (CL) of AMG 224
Description
CL of AMG 224 conjugated antibody, total anti-B-cell maturation antigen (anti-BCMA) antibody and DM1 was measured.
Time Frame
AMG 224: Cycles 1-4 (each cycle = 3 weeks): pre-dose and 0 to 336 hours post-dose; Cycles 5 onwards: pre-dose to 37 days post last dose. DM1: Cycles 1-2 only: pre-dose and 0 to 96 hours post-dose.
Title
Half-life (t1/2) of AMG 224
Description
t1/2 of AMG 224 conjugated antibody, total anti-B-cell maturation antigen (anti-BCMA) antibody and DM1 was measured.
Time Frame
AMG 224: Cycles 1-4 (each cycle = 3 weeks): pre-dose and 0 to 336 hours post-dose; Cycles 5 onwards: pre-dose to 37 days post last dose. DM1: Cycles 1-2 only: pre-dose and 0 to 96 hours post-dose.
Title
Best Overall Response (BOR) According to International Myeloma Working Group Uniform Response Criteria (IMWG-URC)
Description
BOR was the best observed post baseline disease response per IMWG-URC:
Stringent Complete Response (sCR): Negative immunofixation on the serum and urine, soft tissue plasmacytomas disappearance, < 5% plasma cells in bone marrow (BM). Normal serum free light chain ratio and absence of clonal cells in BM Very Good Partial Response (PR[VGPR]): Serum and urine M-protein detectable by immunofixation or ≥ 90% reduction in serum M-protein (urine M-protein level < 100 mg/24-h) PR: ≥ 50% reduction of serum M-protein and 24-hour (h) urinary M-protein by ≥ 90% or to < 200 mg/ 24-h Minor Response (MR): 25%-49% reduction of serum M-protein and 50%-89% in 24-h urinary M-protein, exceeding 200 mg/ 24-h Stable Disease (SD): Not meeting criteria above Progressive Disease (PD): ≥ 25% increase from lowest response value in serum. Development of new or increased size of existing bone lesions or soft tissue plasmacytomas. Hypercalcemia attributed to the plasma cell proliferative disorder
Time Frame
Day 1 of Cycle 1 to up to the end of study (up to 37 days after the last dose), where each cycle is 3 weeks
Title
Time To Progression (TTP) According to International Myeloma Working Group Uniform Response Criteria (IMWG-URC)
Description
TTP was the time from the first administration of AMG 224 to the first objective assessment of disease progression as per IMWG-URC or deaths or if applicable date of censoring.
Time Frame
Day 1 of Cycle 1 to up to the end of study (up to 37 days after the last dose), where each cycle is 3 weeks
Title
Duration of Response (DOR) According to International Myeloma Working Group Uniform Response Criteria (IMWG-URC)
Description
DOR was defined as the time between the date of the first observation indicating an objective response as PR (or better) through to the subsequent date of disease progression as classified by per the IMWG-URC for Multiple Myeloma or death or where applicable date of censoring.
Time Frame
Day 1 of Cycle 1 to up to the end of study (up to 37 days after the last dose), where each cycle is 3 weeks
Title
Percentage of Participants With Conversion to Minimal Residual Disease (MRD)-Negativity
Description
MRD negative was defined as a tumor load of less than 1 clonal cell in 105 normal cells (as determined by flow cytometry). The percentage of participants who converted to be MRD negative was calculated.
Time Frame
Day 1 of Cycle 1 to up to the end of study (up to 37 days after the last dose), where each cycle is 3 weeks
Title
Number of Participants With an Anti-AMG 224 Antibody Formation
Time Frame
Day 1 of Cycle 1 to up to the end of study (up to 37 days after the last dose), where each cycle is 3 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
- Pathologically documented,multiple myeloma relapsed or refractory progressive disease after at least 3 lines of therapy for multiple myeloma.
Prior therapeutic treatment or regimens must include proteasome inhibitors (e.g. bortezomib) and immunomodulatory drugs (e.g. lenalidomide).
Willing and able to undergo bone marrow aspirate per protocol (with or without bone marrow biopsy per institutional guidelines).
Measurable disease per the International Myeloma Working Group (IMWG) response criteria
Hematological function, as follows, without transfusion support:
Absolute neutrophil count ≥ 1.0 X 10^9/L,
Platelet count ≥ 75 X 10^9/L (in patients with < 50% of bone marrow nucleated cells were plasma cells) or ≥ 50 X 10^9/L (in patients with ≥ 50% of bone marrow nucleated cells were plasma cells) without transfusion or growth factor support
Hemoglobin > 8 g/dL (> 80 g/L)
Adequate renal and hepatic function
Left ventricular ejection fraction (LVEF) > 50%
Exclusion Criteria:
Currently receiving treatment in another investigational device or drug study, or less than 28 days since ending treatment on another investigational device or drug study
Autologous stem cell transplant less than 90 days prior to study day 1
Multiple myeloma with IgM subtype
POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) syndrome, Plasma cell leukemia, Waldenstrom's macroglobulinemia or Amyloidosis
Glucocorticoid therapy (prednisone > 30 mg/day or equivalent) within 7 days prior to study day
Myocardial infarction within 6 months of study day 1, symptomatic congestive heart failure (New York Heart Association > class II)
A baseline ECG QTcF > 470 msec
Anti-tumor therapy (chemotherapy, antibody therapy, molecular targeted therapy, or investigational agent) within 28 days prior to study day 1
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
MD
Organizational Affiliation
Amgen
Official's Role
Study Director
Facility Information:
Facility Name
Research Site
City
West Hollywood
State/Province
California
ZIP/Postal Code
90069
Country
United States
Facility Name
Research Site
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Facility Name
Research Site
City
New York
State/Province
New York
ZIP/Postal Code
10065
Country
United States
Facility Name
Research Site
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
Research Site
City
Prahran
State/Province
Victoria
ZIP/Postal Code
3181
Country
Australia
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
IPD Sharing Time Frame
Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
IPD Sharing Access Criteria
Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.
IPD Sharing URL
https://www.amgen.com/datasharing
Citations:
PubMed Identifier
32317775
Citation
Lee HC, Raje NS, Landgren O, Upreti VV, Wang J, Avilion AA, Hu X, Rasmussen E, Ngarmchamnanrith G, Fujii H, Spencer A. Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma. Leukemia. 2021 Jan;35(1):255-258. doi: 10.1038/s41375-020-0834-9. Epub 2020 Apr 21. No abstract available.
Results Reference
background
Links:
URL
http://www.amgentrials.com
Description
AmgenTrials clinical trials website
Learn more about this trial
A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma
We'll reach out to this number within 24 hrs